Yellow Fever Human Infection Model With YF-17D

Last updated: June 12, 2023
Sponsor: Leiden University Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Fever

Treatment

Yellow Fever Vaccine

Clinical Study ID

NCT05901454
NL70951.058.19
  • Ages 18-50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age 18-50 years

Exclusion

Exclusion Criteria:

  • contraindication to receive YF-17D (immune deficiency, thymus illness)
  • previous YF vaccination
  • pregnancy
  • chicken egg allergy
  • hypersensitivity to any other substance in the YF-17D vaccine
  • interval of < 4 weeks of another live attenuated vaccine

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Yellow Fever Vaccine
Phase:
Study Start date:
February 17, 2023
Estimated Completion Date:
March 01, 2024

Study Description

No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.

Connect with a study center

  • Leiden University Medical Center

    Leiden, 2333ZA
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.